<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562080</url>
  </required_header>
  <id_info>
    <org_study_id>ARM-PLUS-LDL</org_study_id>
    <nct_id>NCT01562080</nct_id>
  </id_info>
  <brief_title>Combined Effects of Bioactive Compounds in Lipid Profile</brief_title>
  <acronym>ARM-PLUS-LDL</acronym>
  <official_title>Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Tecnológico de Nutrición y Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rottapharm Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate whether, along with dietary recommendations,
      Armolipid Plus ® can improve the profile of patients with elevated plasma LDL-C acting as a
      change of lifestyle therapy (TLC) according to the definition of Adult Treatment Panel III
      (ATP III)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently reported that the combination of extract of red yeast rice policosanol composed,
      berberine, folic acid and coenzyme Q10 (Armolipid Plus ®, Rottapharm) produced a significant
      improvement in lipid profile in patients with moderately elevated cholesterol levels of low
      density lipoprotein (LDL-C) plasma.

      Taking into account the potential effect of Armolipid Plus ® on the lipid profile, it is
      important to investigate the effectiveness in the field of cardiovascular prevention to
      define its position in prevention programs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>investigate whether the addition of Armolipid Plus ® decreases by 20% LDL-C levels compared to baseline in patients with initial levels of LDL-C ≥ 130 mg / dL.</measure>
    <time_frame>twelve weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk (according to the Framingham tables).</measure>
    <time_frame>twelve weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Criteria for Metabolic Syndrome</measure>
    <time_frame>twelve weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of triglycerides and cholesterol high density lipoprotein (HDL-C).</measure>
    <time_frame>twelve weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Low-density-lipoprotein-type</condition>
  <condition>Elevated Triglycerides</condition>
  <arm_group>
    <arm_group_label>Dietary supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Armolipid Plus</intervention_name>
    <description>one tablet per day during 12 weeks</description>
    <arm_group_label>Dietary supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet per day during 12 weeks</description>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years old

          -  LDL-c plasma levels ≥130 mg/dL and ≤ 189 mg/dL

          -  Patients not requiring lipid-lowering drug treatment according to ATPIII
             guidelines,that do not have cardiovascular disease, stroke or intermittent
             claudication, diabetes mellitus, renal or Patients who have demonstrated effects or
             contraindications to lipid-lowering drug therapy (in this case, treatment should be
             discontinued 1 month before baseline.

          -  Signed and dated informed consent before any study specific procedure.

        Exclusion Criteria:

          -  Patients on drug therapy to reduce LDL-C, for example, statins, bile acid
             sequestrants, nicotinic acid, fibrates or similar (up to 1 month before baseline).

          -  History of cardiovascular disease, stroke or intermittent claudication.

          -  Diabetes mellitus (at least 2 blood fasting glucose greater than 126 mg / dL).

          -  Having taken any functional food with sterols, stanols or similar or any nutraceutical
             with lipid-lowering effects during the previous 7 days.

          -  Plasma levels of triglycerides &gt; 350 mg/dl

          -  Diagnosis of familial hypercholesterolemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Solà, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hosp. Universitari Sant Joan de Reus (Tarragona)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Millán, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario Gregorio Marañón (Madrid)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José R Calabuig, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario La Fe (Valencia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Villar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario Virgen del Rocío (Sevilla)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Puzo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario San Jorge (Huesca)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Brea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario San Pedro ( Logroño)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hosp. Universitario San Joan</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>yeast red</keyword>
  <keyword>berberine</keyword>
  <keyword>policosanol</keyword>
  <keyword>astaxanthin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Policosanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

